These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37381026)

  • 1. Currently recommended skin scores correlate highly in the assessment of patients with Juvenile Dermatomyositis (JDM).
    Gebreamlak A; Sawicka KM; Garrett R; Goh YI; Baker KM; Feldman BM
    Pediatr Rheumatol Online J; 2023 Jun; 21(1):63. PubMed ID: 37381026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the Utility and Validity of Three Scoring Tools to Measure Skin Involvement in Patients With Juvenile Dermatomyositis.
    Campanilho-Marques R; Almeida B; Deakin C; Arnold K; Gallot N; de Iorio M; Nistala K; Pilkington CA; Wedderburn LR;
    Arthritis Care Res (Hoboken); 2016 Oct; 68(10):1514-21. PubMed ID: 26881696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool-Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists.
    Tiao J; Feng R; Berger EM; Brandsema JF; Coughlin CC; Khan N; Kichula EA; Lerman MA; Lvovich S; McMahon PJ; Rider LG; Rubin AI; Scalzi LV; Smith DM; Taxter AJ; Treat JR; Williams RP; Yum SW; Okawa J; Werth VP
    Br J Dermatol; 2017 Oct; 177(4):1086-1092. PubMed ID: 28421601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis.
    Klein RQ; Bangert CA; Costner M; Connolly MK; Tanikawa A; Okawa J; Rose M; Fakharzadeh SS; Fiorentino D; Lee LA; Sontheimer RD; Taylor L; Troxel AB; Werth VP
    Br J Dermatol; 2008 Sep; 159(4):887-94. PubMed ID: 18616782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change.
    Anyanwu CO; Fiorentino DF; Chung L; Dzuong C; Wang Y; Okawa J; Carr K; Propert KJ; Werth VP
    Br J Dermatol; 2015 Oct; 173(4):969-74. PubMed ID: 25994337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary function and autoantibodies in a long-term follow-up of juvenile dermatomyositis patients.
    Mathiesen PR; Buchvald F; Nielsen KG; Herlin T; Friis T; Nielsen S
    Rheumatology (Oxford); 2014 Apr; 53(4):644-9. PubMed ID: 24310298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis.
    Ahmed S; Chakka S; Concha J; Krain R; Feng R; Werth VP
    Br J Dermatol; 2020 Apr; 182(4):949-954. PubMed ID: 31206600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI).
    Rider LG; Werth VP; Huber AM; Alexanderson H; Rao AP; Ruperto N; Herbelin L; Barohn R; Isenberg D; Miller FW
    Arthritis Care Res (Hoboken); 2011 Nov; 63 Suppl 11(0 11):S118-57. PubMed ID: 22588740
    [No Abstract]   [Full Text] [Related]  

  • 9. Update on Epidemiology and Clinical Assessment Tools of Cutaneous Lupus Erythematosus and Dermatomyositis.
    Chang YC; Werth VP
    Curr Dermatol Rep; 2013 Mar; 2(1):48-57. PubMed ID: 33585073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis.
    Rosina S; Consolaro A; van Dijkhuizen P; Pistorio A; Varnier GC; Bovis F; Nistala K; Maillard S; Civino A; Tsitsami E; de Inocencio J; Jelusic M; Vojinovic J; Espada G; Makay B; Katsicas MM; Pratsidou-Gertsi P; Lazarevic D; Rao AP; Pires Marafon D; Martini A; Pilkington C; Ruperto N; Ravelli A
    Rheumatology (Oxford); 2019 Jul; 58(7):1196-1205. PubMed ID: 30690571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM.
    Goreshi R; Okawa J; Rose M; Feng R; Lee LA; Hansen CB; Bangert CA; Connolly MK; Davis MD; Callen JP; Fett NM; Fakharzadeh SS; Clarke JT; Werth VP
    J Invest Dermatol; 2012 Apr; 132(4):1117-24. PubMed ID: 22217740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis.
    Huber AM; Dugan EM; Lachenbruch PA; Feldman BM; Perez MD; Zemel LS; Lindsley CB; Rennebohm RM; Wallace CA; Passo MH; Reed AM; Bowyer SL; Ballinger SH; Miller FW; Rider LG;
    Arthritis Rheum; 2008 Feb; 59(2):214-21. PubMed ID: 18240194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument.
    Yassaee M; Fiorentino D; Okawa J; Taylor L; Coley C; Troxel AB; Werth VP
    Br J Dermatol; 2010 Mar; 162(3):669-73. PubMed ID: 19863510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of a score tool for measurement of histological severity in juvenile dermatomyositis and association with clinical severity of disease.
    Varsani H; Charman SC; Li CK; Marie SK; Amato AA; Banwell B; Bove KE; Corse AM; Emslie-Smith AM; Jacques TS; Lundberg IE; Minetti C; Nennesmo I; Rushing EJ; Sallum AM; Sewry C; Pilkington CA; Holton JL; Wedderburn LR;
    Ann Rheum Dis; 2015 Jan; 74(1):204-10. PubMed ID: 24064003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome in patients with juvenile dermatomyositis: A case series.
    Chevalier G; Fakih O; Lhose A; Ballot-Schmit C; Prati C; Puzenat E; Aubin F
    Arch Pediatr; 2021 Aug; 28(6):475-479. PubMed ID: 34034928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab.
    Aggarwal R; Loganathan P; Koontz D; Qi Z; Reed AM; Oddis CV
    Rheumatology (Oxford); 2017 Feb; 56(2):247-254. PubMed ID: 27837048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool.
    Sanner H; Sjaastad I; Flatø B
    Rheumatology (Oxford); 2014 Sep; 53(9):1578-85. PubMed ID: 24692575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Juvenile-onset clinically amyopathic dermatomyositis: an overview of recent progress in diagnosis and management.
    Walling HW; Gerami P; Sontheimer RD
    Paediatr Drugs; 2010; 12(1):23-34. PubMed ID: 20034339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative scoring of the Cutaneous Assessment Tool in juvenile dermatomyositis: results using abbreviated formats.
    Huber AM; Lachenbruch PA; Dugan EM; Miller FW; Rider LG;
    Arthritis Rheum; 2008 Mar; 59(3):352-6. PubMed ID: 18311761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Juvenile dermatomyositis: advances in pathogenesis, evaluation, and treatment.
    Huber AM
    Paediatr Drugs; 2009; 11(6):361-74. PubMed ID: 19877722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.